Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Standard
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. / Podlekareva, Daria; Mocroft, Amanda; Post, Frank A; Riekstina, Vija; Miro, Jose M; Furrer, Hansjakob; Bruyand, Mathias; Panteleev, Alexander M; Rakhmanova, Aza G; Girardi, Enrico; Losso, Marcello H; Toibaro, Javier J; Caylá, Joan; Miller, Rob F; Obel, Niels; Skrahina, Alena; Chentsova, Nelly; Lundgren, Jens; Kirk, Ole; HIV/TB Study Writing Group.
I: AIDS, Bind 23, Nr. 18, 2009, s. 2485-95.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina
AU - Podlekareva, Daria
AU - Mocroft, Amanda
AU - Post, Frank A
AU - Riekstina, Vija
AU - Miro, Jose M
AU - Furrer, Hansjakob
AU - Bruyand, Mathias
AU - Panteleev, Alexander M
AU - Rakhmanova, Aza G
AU - Girardi, Enrico
AU - Losso, Marcello H
AU - Toibaro, Javier J
AU - Caylá, Joan
AU - Miller, Rob F
AU - Obel, Niels
AU - Skrahina, Alena
AU - Chentsova, Nelly
AU - Lundgren, Jens
AU - Kirk, Ole
AU - HIV/TB Study Writing Group
PY - 2009
Y1 - 2009
N2 - BACKGROUND AND OBJECTIVES: Tuberculosis (TB) is a leading cause of death in HIV-infected patients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina. METHODS: One-year mortality was assessed in patients stratified according to region of residence, and factors associated with death were evaluated in multivariable Cox models. RESULTS: At TB diagnosis, patients in Eastern Europe had less advanced immunodeficiency, whereas a greater proportion had a history of intravenous drug use, coinfection with hepatitis C, disseminated TB, and infection with drug-resistant TB (P < 0.0001). In Eastern Europe, fewer patients initiated TB treatment containing at least rifamycin, isoniazid, and pyrazinamide or combination antiretroviral therapy (P < 0.0001). Mortality at 1 year was 27% in Eastern Europe, compared with 7, 9 and 11% in Central/Northern Europe, Southern Europe, and Argentina, respectively (P < 0.0001). In a multivariable model, the adjusted relative hazard of death was significantly lower in each of the other regions compared with Eastern Europe: 0.34 (95% confidence interval 0.17-0.65), 0.28 (0.14-0.57), 0.34 (0.15-0.77) in Argentina, Southern Europe and Central/Northern Europe, respectively. Factors significantly associated with increased mortality were CD4 cell count less than 200 cells/microl [2.31 (1.56-3.45)], prior AIDS [1.74 (1.22-2.47)], disseminated TB [2.00 (1.38-2.85)], initiation of TB treatment not including rifamycin, isoniazid and pyrazinamide [1.68 (1.20-2.36)], and rifamycin resistance [2.10 (1.29-3.41)]. Adjusting for these known confounders did not explain the increased mortality seen in Eastern Europe. CONCLUSION: The poor outcome of patients with HIV/TB in Eastern Europe deserves further study and urgent public health attention.
AB - BACKGROUND AND OBJECTIVES: Tuberculosis (TB) is a leading cause of death in HIV-infected patients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina. METHODS: One-year mortality was assessed in patients stratified according to region of residence, and factors associated with death were evaluated in multivariable Cox models. RESULTS: At TB diagnosis, patients in Eastern Europe had less advanced immunodeficiency, whereas a greater proportion had a history of intravenous drug use, coinfection with hepatitis C, disseminated TB, and infection with drug-resistant TB (P < 0.0001). In Eastern Europe, fewer patients initiated TB treatment containing at least rifamycin, isoniazid, and pyrazinamide or combination antiretroviral therapy (P < 0.0001). Mortality at 1 year was 27% in Eastern Europe, compared with 7, 9 and 11% in Central/Northern Europe, Southern Europe, and Argentina, respectively (P < 0.0001). In a multivariable model, the adjusted relative hazard of death was significantly lower in each of the other regions compared with Eastern Europe: 0.34 (95% confidence interval 0.17-0.65), 0.28 (0.14-0.57), 0.34 (0.15-0.77) in Argentina, Southern Europe and Central/Northern Europe, respectively. Factors significantly associated with increased mortality were CD4 cell count less than 200 cells/microl [2.31 (1.56-3.45)], prior AIDS [1.74 (1.22-2.47)], disseminated TB [2.00 (1.38-2.85)], initiation of TB treatment not including rifamycin, isoniazid and pyrazinamide [1.68 (1.20-2.36)], and rifamycin resistance [2.10 (1.29-3.41)]. Adjusting for these known confounders did not explain the increased mortality seen in Eastern Europe. CONCLUSION: The poor outcome of patients with HIV/TB in Eastern Europe deserves further study and urgent public health attention.
U2 - 10.1097/QAD.0b013e3283326879
DO - 10.1097/QAD.0b013e3283326879
M3 - Journal article
C2 - 19898216
VL - 23
SP - 2485
EP - 2495
JO - AIDS
JF - AIDS
SN - 1350-2840
IS - 18
ER -
ID: 19663757